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Abstract
Background—TNF/TNFR superfamily members conform a group of molecular interaction 
pathways of essential relevance during the process of T cell activation and differentiation towards 
effector cells and particularly for the maintenance phase of the immune response. Specific 
blockade of these interacting pathways, such as CD40/CD40L, contributes to modulate the 
deleterious outcome of allogeneic immune responses. We postulated that antagonizing the 
interaction of LIGHT expression on activated T cells with its receptors, HVEM and LTβR may 
decrease T cell-mediated allogeneic responses.
Methods—A flow cytometry competition assay was designed to identify anti-LIGHT 
monoclonal antibodies capable to prevent the interaction of mouse LIGHT with its receptors 
expressed on transfected cells. An antibody with the desired specificity was evaluated in a short-
term in vivo allogeneic cytotoxic assay and tested for its ability to detect endogenous mouse 
LIGHT.
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Results—We provide evidence for the first time that in mice, as previously described in humans, 
LIGHT protein is rapidly and transiently expressed after T cell activation, and this expression was 
stronger on CD8 T cells than on CD4 T cells. Two anti-LIGHT antibodies prevented interactions 
of mouse LIGHT with its two known receptors HVEM and LTβR. In vivo administration of anti-
LIGHT antibody (clone 10F12) ameliorated host anti-donor short-term cytotoxic response in WT 
B6 mice, although to a lesser extent than that observed in LIGHT-deficient mice.
Conclusions—The therapeutic targeting of LIGHT may contribute to achieve a better control of 
cytotoxic responses refractory to current immunosuppressive drugs in transplantation.
Keywords
HVEM (TNFRSF14); LIGHT (TNFSF14); LTβR (TNFRSF3); DcR3 (TNFRSF6b); co-
stimulation; transplantation; alloreactivity; graft rejection; graft versus host disease; cytotoxicity
Introduction
Human LIGHT (homologous to lymphotoxin, exhibits inducible expression and competes 
with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on 
T lymphocytes) is a member of the TNF superfamily transiently detected on human T cells 
upon activation (1,2) and immature dendritic cells (3,4). Mouse LIGHT is a type II 
transmembrane protein of 239 amino acids, with an extracellular region 74% similar in 
amino acid sequence to human LIGHT (1,5).
LIGHT can act as a costimulatory molecule independently of CD28 (3,4), fostering T cell 
proliferation in the mixed lymphocyte reaction and promoting the process of DC maturation 
as well (6). It can even augment antitumor activity directly (7) or indirectly through 
enhancing CTL activity against tumor cells (4). In line with the costimulatory activity of 
LIGHT, constitutive transgenic expression of LIGHT under the control of a T cell-specific 
promoter led to chronic inflammation of mucosal tissues (8,9). In contrast, gene deletion of 
LIGHT results in defective CD8 T cell proliferation and acquisition of CTL effector 
function, which is associated with prolonged graft survival in several allogeneic mouse 
models of transplantation (10-13).
One of the LIGHT receptors is HVEM (TNFRSF14), which is broadly expressed on 
hematopoietic and non hematopoietic cells (14,15). HVEM is a type I transmembrane 
molecule with an extracellular portion divided into cysteine-rich domains (CRD1-4) (16-18) 
with distinct binding sites for its ligands. BTLA and CD160 bind to the CRD1 and part of 
the CRD2 of HVEM, and so does the viral protein gD of Herpes Simplex Virus (HSV) 
(19,20), whereas LIGHT interacts with CRD2 and CRD3 on opposite sides of the 
extracellular part of HVEM (21). Furthermore, membrane LIGHT can be released by the 
action of a metalloprotease (22) and the soluble form of LIGHT binds to BTLA/HVEM 
complex and strengthens the molecular interaction, whereas engagement of membrane 
anchored HVEM by LIGHT in cis displaces BTLA from its interaction with HVEM and 
allows bidirectional trans co-stimulatory contacts between HVEM and LIGHT (1,23,24).
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The other well-characterized receptor of LIGHT is the LTβR, which is expressed on 
follicular dendritic cells (FDCs), dendritic cells (DCs), macrophages, stromal cells and high 
endothelial venules (HEV) (25). LTαβ CD4+CD3− inducer cells interact with LTβR on 
stromal organizer cells to guide lymphoid organogenesis during development and, later on, 
stroma-derived LTβR signaling is still essential for the maintenance of the lymphoid tissue 
structure (26,27). LTαβ expression on activated CD4+ helper T cells (28) and LTβR on DCs 
and B cells follows a similar pattern to that of CD40L and CD40 expression on T cells and 
antigen presenting cells respectively, suggesting that LTαβ/LTβR pathway may regulate the 
exchange of information between antigen presenting cells and T cells, and therefore 
participate in T cell activation and differentiation. LIGHT expressed on activated T cells 
may provide a licensing signal upon interaction with LTβR expressed on DC (6) or on 
stromal cells that would in turn modify the lymphoid tissue environment to achieve proper T 
cell priming.
So far, there have been no reagents available capable to specifically recognize 
conformational epitopes on the extracellular region of the mouse LIGHT, although reagents 
against human LIGHT are available (6), (29). In an attempt to define the therapeutic 
potential of targeting LIGHT in animal model systems, and to detect and follow membrane 
LIGHT expression, rat monoclonal antibodies against mouse LIGHT were raised and 
selected based on their ability to block the binding of soluble LTβR-Ig or HVEM-Ig to 
LIGHT-transduced cells. Their therapeutic activity was then assessed in an in vivo mouse 
model of alloreactivity and we demonstrated that the specific blockade of LIGHT mitigated 
the in vivo cytotoxic allogeneic immune response. These observations pointed out that 
LIGHT/HVEM/LTβR interacting pathway is an amenable therapeutic target for the immune 
intervention for the control of cell-mediated cytotoxic responses.
Results
Conserved cross-interactions between mouse LIGHT receptors and mouse and human 
LIGHT
The TNF receptor-binding domain of LIGHT interacts with CRD2 and CRD3 on one side of 
membrane anchored HVEM, whereas BTLA and CD160 interact with CRD1 and CRD2 on 
the opposite side of HVEM (2,21,30). According to molecular modeling and previous 
studies, the receptors HVEM, LTβR and DcR3 share widely overlapping binding sites on 
LIGHT (2). DcR3 is a soluble decoy receptor that is present in human but has no known 
counterpart in mouse. Interactions of mouse LIGHT with its receptors are not very well 
documented, in part due to the difficulty of preparing active soluble mouse LIGHT (31). We 
indeed found that either recombinant soluble mouse LIGHT fused to an IgG2a Fc fragment, 
or LIGHT multimerized with an isoleucine zipper, failed to bind its receptors (data not 
shown) (32). However, a third soluble form of mouse LIGHT, containing amino acids 
72-239 linked to a Flag-Foldon tag proved to be active and efficiently reacted with mouse 
HVEM, mouse LTβR and human DcR3 expressed as full-length or glycolipid-anchored 
proteins on HEK-293T cells (Figure 1A). Human LIGHT gave a similar binding pattern, 
except that its binding to mouse LTβR was weaker in this particular experimental setting 
(Figure 1A). Similar results were obtained when cells expressing full-length mouse or 
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human LIGHT were stained with receptor.Ig fusion proteins. In these experiments, mouse 
HVEM and mouse LTβR bound to mouse and human LIGHT, whereas human DcR3 gave 
weaker stainings (Figure 1B).
Taken together, the binding results indicate that in the mouse system, LIGHT indeed binds 
the relevant receptors HVEM and LTβR, which is in agreement with and extends 
conclusions of previous reports describing the binding interactions between LIGHT and its 
natural receptors (7,31).
Differential competition of soluble forms of LTβR and HVEM for binding to LIGHT
HVEM delivers costimulatory signals to T cells when engaged by LIGHT, while LIGHT/ 
LTβR functionally modulates dendritic cells and stromal cells to promote an adequate 
environment for T cell priming (33,34). Since both LTβR and HVEM bind to LIGHT, when 
both receptors are simultaneously expressed in cis (on the same cell) or in trans (in different 
cells), the advantageous competition of one of the receptors over the other would displace 
the less competitive receptor from interacting with LIGHT (2). Under those circumstances, 
binding of the receptor with the highest affinity may dominate a particular signaling 
pathway. Saturation LIGHT binding curves were established for mHVEM.IgG2a (HVEM-
Ig) and for mLTβR.IgG1 (LTβR-Ig). Interestingly, concentrations of receptors required to 
achieve saturation binding was about 20-fold higher for HVEM-Ig than for LTβR-Ig (Figure 
2A). LIGHT-transduced cells preincubated with a saturated amount of soluble HVEM-Ig did 
not prevent LTβR-Ig from binding to LIGHT (Figure 2B, left lower panel). In contrast, 
preincubation of LIGHT transduced cells with LTβR-Ig completely abrogated the binding of 
HVEM-Ig to LIGHT-transduced cells (Figure 2B, right lower panel).
These experiments suggest that HVEM, at least in its recombinant form, has a lower affinity 
for mouse LIGHT than for mouse LTβR and confirm that HVEM and LTβR binding sites on 
LIGHT overlap.
Anti-LIGHT antibodies that efficiently recognize and block mouse LIGHT
A LIGHT-transduced NIH-3T3 cell line coexpressing eGFP (clone 2B7) was obtained by 
limiting dilution cloning and used as immunogen in rats to produce anti-mouse LIGHT 
hybridomas. Hybridoma supernatants were screened for their recognition of mouse LIGHT 
by flow cytometry using LIGHT-GFP- or control GFP-transduced NIH-3T3 cell lines. Four 
rat IgG2a anti-LIGHT antibodies (10F12, 3G1, 6H12 and 9B7) specifically recognized an 
epitope located at the extracellular region of mouse LIGHT (Figure 3A, left panels). Of note, 
all four antibodies cross-reacted with human LIGHT expressed on transiently transfected 
HEK-293T cells (Figure 3A, right panels).
Anti-LIGHT antibodies were screened for their ability to prevent the binding of HVEM-Ig 
and LTβR-Ig to LIGHT-transduced cells. Two anti-LIGHT antibodies (10F12 and 3G1) 
fully prevented the binding of HVEM-Ig to mouse LIGHT-expressing cells in a FACS-
based assay, whereas antibodies 9B7 and 6H12 did not (Figure 3B). Anti-LIGHT, clone 
10F12 was the most potent antibody to inhibit the binding of LTβR-Ig to mouse LIGHT, 
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although inhibition did not reach baseline, whereas 3G1 only partially inhibited this 
interaction (Figure 3B).
Anti-LIGHT mAb 10F12 was further characterized in a binding assay between membrane-
bound and soluble LIGHT, in which 10F12 binding to membrane-bound LIGHT is 
competed by soluble Flag-Foldon (FF)-LIGHT (Figure 3C). At the EC50, 10F12 and FF-
LIGHT were at equimolar concentrations, indicating no obvious bias of 10F12 to recognize 
membrane-bound LIGHT, and therefore validating the quality of soluble recombinant FF-
LIGHT. The ability of 10F12 to prevent the binding of FF-LIGHT to membrane-bound 
HVEM and LTβR was then investigated (Figures 3D, E). 10F12 inhibited the binding of FF-
LIGHT to both full-length HVEM and GPI-anchored LTβR with a similarly good efficiency: 
at EC50, the ratio of antibody binding sites to FF-LIGHT epitopes was stoichiometric, and a 
five-fold molar excess of antibody to LIGHT totally abrogated LIGHT binding to both 
receptors (Figures 3D, E). Of the nineteen mouse TNF family members, 10F12 only 
recognized LIGHT in a sandwich ELISA assay, validating its binding specificity (Figure 
3F). The affinity of the interaction of FF-LIGHT with a monomeric Fab fragment of 10F12 
prepared by ficin digestion (Fig. 3G) was measured by surface plasmon resonance. The 
association rate constant (ka) was 4.2×105 M−1 s−1, the dissociation rate constant (kd)) was 
2.3×10−3 s−1 and the affinity (KD) was 5.4 nM (Rmax: 176, Chi2: 3.4) (Figure 3H). For 
comparison, a panel of Fab from agonist anti-EDAR antibodies with in vivo activity had kd 
ranging from 9.6 to 0.24 ×10−3 s−1 (the smallest the number, the better the antibody sticks to 
its antigen once bound) and affinities from 0.5 - 40 nM (35).
In summary, we have identified both blocking and non-blocking monoclonal antibodies 
recognizing surface-exposed mouse LIGHT that cross-reacted with human LIGHT. One of 
these antibodies had decent binding parameters and showed efficient and specific blockade 
of the interaction of LIGHT with its two receptors, making it possible for the first time to 
monitor the expression of mouse LIGHT at protein level and to conduct LIGHT-blocking 
therapeutic experiments in mice.
Mouse LIGHT is transiently expressed on activated CD8 T cells and NK cells, and to a 
lesser extent in CD4 T cells
Anti-LIGHT antibodies were tested for their ability to detect endogenous LIGHT. 
Considering that in humans, LIGHT protein is not detectable on resting T cells, fresh mouse 
B6 WT and B6 LIGHT KO splenocytes were stimulated in vitro with PMA plus ionomycin 
for 5 h in the presence of either HiLyte-647 labeled anti-LIGHT (10F12) or HiLyte-647-
labeled rat IgG2a isotype control. This strong polyclonal T cell activation prompted a 
transient expression of LIGHT that was readily detected in virtually all CD8 T cells and to a 
lower extent in a subset of CD4 T cells of WT B6 mice, but not in LIGHT-deficient T cells 
(Figure 4A), in line with the previous description of LIGHT expression in human T cells 
(29), (1). Polyclonal activation with PMA plus ionomycin also induced transient expression 
of LIGHT on NK cells, but not in similarly stimulated LIGHT KO NK1.1 cells (Figure 4B). 
Because of the transient expression of LIGHT in activated T cells, it is noteworthy to 
mention that the labeled antibody needs to be present during the course of activation in order 
to achieve successful detection.
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In vivo allogeneic cytotoxic activity is significantly reduced after antibody-mediated 
blockade of the LIGHT/HVEM/LTβR pathway, although to a lesser extent than in LIGHT-
deficient mice
To elucidate whether antibody blockade of the LIGHT/HVEM/LTβR pathway could 
modulate allogeneic cytotoxic responses, B6 recipient mice were injected with an identical 
number of B6, BALB/c and F1 target cells labeled with different amounts of CFSE, as 
mentioned in the Material and Methods section. As shown in figure 5, the percentage of 
killing of allogeneic BALB/c and F1 target cells in host B6 spleen (Figure 5A) and 
peripheral lymph nodes (Figure 5B) was significantly reduced in LIGHT-deficient mice 
compared to B6 WT mice (BALB/c target cells: spleen and pLNs, p<0.0005 and F1 target 
cells: spleen and pLNs, p<0.005). In line with these results, antagonist anti-LIGHT 
monoclonal antibody 10F12 significantly mitigated host anti-donor cytotoxic responses 
against BALB/c target cells (spleen, p<0.005 and pLNs, p<0.05), and showed a trend 
towards protection of F1 targets that however did not reach statistical significance (Figure 
5A and 5B).
As the cytolytic response was diminished in LIGHT KO mice and also to a certain extent in 
anti-LIGHT-treated WT mice, we evaluated whether donor alloreactive T cell proliferation 
would be altered in semiallogeneic F1 recipients. Donor LIGHT KO CD4 and CD8 T cells 
proliferated significantly less efficiently than isotype control or anti-LIGHT treated donor 
WT T cells in the spleen of adoptively transferred F1 recipients (Figure 5C). Moreover, this 
observation correlated with a diminished frequency of LIGHT KO donor alloreactive CD4 T 
cells and CD8 T cells (Figure 5D) expressing IL-2Rα when compared to isotype- or anti-
LIGHT treated WT donor T cells adoptively transferred into semiallogeneic F1 recipients.
Therefore, this short-term in vivo cytotoxic assay reveals that in vivo administration of anti-
LIGHT mAb ameliorated the host anti-donor short-term cytotoxic response in WT B6 mice 
although to a lesser extent than that observed in LIGHT-deficient mice.
Discussion
The development of biologics aimed at preventing receptor / ligand interactions between 
TNF/TNFR molecules are alternative therapeutic arms of interest to conventional 
immunosuppression for the control of alloreactivity (14), (36). One of such therapeutic 
targets is the process of T cell activation and differentiation that drives the acquisition of 
effector T cell function. The molecules involved in the exchange of information between 
DC/T, B/T and T/T cell interactions belong to two major families of proteins, the 
Immunoglobulin (Ig) superfamily and the Tumor Necrosis Factor / Tumor Necrosis Family 
Receptor Superfamily (TNF/TNFRSF), the latter exhibiting cysteine-rich domains in the 
extracellular region of the molecule (31,37).
In this work, we provide for the first time a monoclonal antibody capable to detect LIGHT 
expression on mouse T cells and NK cells, and that additionally blocks the receptor binding 
site of LIGHT. We also demonstrated that therapeutic intervention with this antagonist anti-
LIGHT antibody protected to some extent against rejection, although it did not fully 
recapitulate the attenuated cytotoxic immune response seen in LIGHT-deficient mice.
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Although numerous reports in mouse models of inflammatory diseases have provided 
indirect experimental evidence that LIGHT may be involved in the pathogenesis of these 
immune-related diseases (10,38-42), this information contrasts with the lack of appropriate 
reagents for the detection of endogenous mouse LIGHT. The reason for this gap was the 
difficulty to engineer a genetic construct that produced a bioactive mouse LIGHT molecule 
with binding affinity for membrane-bound LIGHT receptors. We and others have evaluated 
a classical approach of fusing the extracellular region of mouse LIGHT either to Flag, the Fc 
fragment of the immunoglobulin heavy chain, or to an isoleucine zipper for the 
multimerization of the molecule (32), but none of these engineered genetic constructs 
succeeded in generating a protein with detectable binding affinity for mouse HVEM and 
LTβR. This was possible through a strategy that consisted of fusing the extracellular region 
of mouse LIGHT to a Flag-Foldon tag at the C-terminal site of this type II transmembrane 
protein (7).
Human LIGHT is constitutively expressed on intestinal mucosal CD8 T cells, CD4 T cells 
and NK cells and this expression is inducible by CD2-mediated signaling, which correlates 
with the typical activated state of resident lymphoid cells populating the intestinal mucosa 
(43), (44). In contrast to mucosal sites, in peripheral blood, LIGHT is inducible after 
exposure to PMA/ionomycin in CD8 T cells and to a similar extent in CD4+/CD45RO 
memory T cells and in CD4 Th1 IFN-γ producer cells and this expression was higher than 
that detected on naive CD4 T cells (44). The differential expression of LIGHT in humans, 
which is constitutive on lymphocytes of mucosal tissues and inducible on peripheral blood 
lymphocytes, indicates that regulation of LIGHT expression is associated with an activation 
and responsive status of the lymphoid cell. These results are in agreement with the observed 
transient expression of LIGHT on mouse peripheral lymphoid cells upon exposure to PMA/
Ionomycin for 5 hours, indicating a similar regulation of inducible expression on peripheral 
blood of both human and mouse. This suggests that mice models of disease may contribute 
to unravel the physiology of LIGHT and its role during the course and in the context of an 
allogeneic response.
LIGHT (TNFSF14) and CD40L (also named CD154, TNFSF5) are both members of the 
TNF ligand superfamily. CD40L expression is not detectable on naive T cells (45) and the 
same holds true for the expression of human LIGHT (29), which is agreement with the 
observation in our work that LIGHT expression is neither detectable on naïve T cells and 
NK cells and was only seen transiently upon T cell activation with a strong polyclonal 
stimulus. As a matter of fact, mouse LIGHT protein detection needed the presence of the 
fluorescently-conjugated antibody against LIGHT during in vitro stimulation of T cells and 
NK cells. This is probably due to the fact that LIGHT is rapidly internalized after transient 
surface exposure. Contrary to CD40L, which is mainly expressed on CD4 T cells, mouse 
LIGHT presents a more pronounced expression on CD8 T cells than on CD4 T cells, 
suggesting a more predominant functional role on this T cell subset.
TcR recognition of a foreign peptide in the context of MHC along with costimulation drives 
T cell activation, IL-2 secretion and up-regulation of IL-2Rα chain (CD25), which 
associates with beta and gamma chain of IL-2 to configure the high affinity IL-2R. This 
permits IL-2-mediated autocrine CD4 T cell proliferation and clonal expansion and provides 
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help for CD8 T cell clonal expansion and differentiation to effector CD8 T cells. In vitro 
studies with LIGHT KO CD4 T cells evidenced a deficiency in IL-2 secretion compared to 
WT CD4 T cells in response to polyclonal activation with anti-CD3/CD28 (11), which was 
also noticeable in the mixed lymphocyte reaction (12). The lack of secreted IL-2 likely 
contributes to the impaired CD8 T cell proliferation and differentiation to effector T cells, 
which also express less CD25 and therefore would proliferate less efficiently in response to 
IL-2 (12), (11). In agreement with this defective in vitro functional activity, our data also 
reflected similar defects in vivo such as a lower frequency of donor alloreactive CD4 and 
CD8 T cells expressing the IL-2Rα chain and decreased proliferative rate observed in F1 
recipients receiving LIGHT KO semiallogeneic splenocytes compared to F1 recipients 
receiving semiallogeneic B6 WT splenocytes either treated with isotype control or with anti-
LIGHT mAb.
The treatment of mice with soluble decoy receptors administered as recombinant fusion 
proteins disrupts various ligand/receptor interactions simultaneously. Despite the indirect 
evidences collected from the use of these decoy receptors on different mouse models of 
allogeneic transplantation, these approaches do not provide clear evidence on whether 
LIGHT could be a potential target for immune intervention. For example, the administration 
of decoy receptors, such as HVEM-Ig, LTβR-Ig or sDcR3-Ig attenuates alloreactivity in 
murine models of disease, but it is difficult to conclude whether the observed outcome is the 
result of inhibiting LIGHT interaction with its receptors and to which extent the observed 
effects might be due in part to inhibition of other ligands such as lymphotoxin or FasL 
(4,46-48). Therefore, assignment of the most significant ligand/receptor pathway responsible 
for the observed in vivo effect is inherently difficult. Another consideration is that most of 
the decoy receptors used in preclinical rodent models of transplantation are composed of the 
extracellular region of the receptor bound to human IgG1 Fc fragment. It is well known that 
human IgG1 binds efficiently to mouse FcγRIV, the main receptor in mice involved in 
ADCC-mediated depletion by myeloid cells and NK cells (49). This means that many claims 
in the literature stating that these decoy receptors function as blocking reagents can be 
biased if depletion of ligand-expressing cells indeed may occur.
In contrast to recombinant fusion proteins, selective antibody-based approaches targeting 
one particular ligand/receptor interaction will likely provide more relevant information than 
the use of soluble decoy receptors. The selective antibody-mediated blockade of the LIGHT/
HVEM/LTβR pathway prevented the in vivo host anti-donor cytotoxic alloresponse, 
although to a lesser extent than that seen in LIGHT-deficient mice. The relative lack of 
efficacy of the antibody in vivo was unexpected given the stoichiometric inhibition of 
LIGHT by the antibody in vitro and the favorable antibody to ligand ratio that can be 
achieved in vivo. Perhaps recombinant and over-expressed proteins used in vitro 
underestimated the binding affinity of LIGHT for its receptors in vivo, and 10F12 only 
partially blocked endogenous LIGHT. In this case, we predict that residual signaling may be 
preferentially delivered through LTβR, for which LIGHT has a higher affinity. 
Alternatively, LIGHT may engage its receptors in vivo in the immunological synapses 
established between cells that may exclude extracellular medium containing the antibody. 
Finally, it is also conceivable that, because of a life-long deficiency of LIGHT, LIGHT-ko 
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mice are intrinsically hyporesponsive, a phenotype that could not be reproduced by an acute, 
even full inhibition of LIGHT. Although LIGHT deficiency has been associated with 
impaired lymphocyte migration to lymph nodes, this only occurred under strong 
inflammatory conditions, which are not present in our experimental in vivo cytotoxic setting. 
This rules out the possibility that the observed reduction of cytotoxicity in LIGHT deficient 
mice or anti-LIGHT treated mice was a consequence of reduced migration of the target cells 
to these secondary lymphoid organs (50).
In summary, we report for the first time specific blocking and non-blocking monoclonal 
antibodies against mouse LIGHT as new reagents in the field of TNF/TNFR interactions to 
follow LIGHT protein expression and explore the preclinical consequences of interrupting 
LIGHT interactions with its receptors. We also demonstrated that targeting LIGHT may 
offer novel avenues for the control of cytotoxic responses in the setting of transplantation.
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List of abbreviations
LIGHT homologous to lymphotoxin, exhibits inducible expression 
and competes with HSV glycoprotein D for binding to 
herpesvirus entry mediator, a receptor expressed on T 
lymphocytes
mAb monoclonal antibody
GvHR Graft versus host reaction
CD Cluster of differentiation
HSV Herpesvirus
HVEM Herpesvirus entry mediator
CRD Cysteine rich domain
APC Antigen presenting cells
FDC Follicular dendritic cell
TNF Tumor necrosis factor
LTβR Lymphotoxin beta receptor
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DC Dendritic cell
CTL Cytotoxic T lymphocyte
NK Natural killer
WT Wild type
KO Knock-out
mGFP monster green fluorescent protein
eGFP enhanced green fluorescent protein
APC Allophycocyanin
PE Phycoerythrin
MHC Major Histocompatibility Complex
GPI Glycosylphosphatidylinositol
PMA Phorbol myristate acetate
CFSE Carboxyfluorescein succinimidyl ester
Flag-shLIGHT Flag-tagged soluble human LIGHT
FF-LIGHT Flag-Foldon-tagged soluble mouse LIGHT
HVEM-Ig: 
HVEM.mIgG2a.Fc
Herpesvirus entry mediator bound to mouse IgG2a Fc 
fragment.
LTβR-Ig: LTβR.huIgG1.Fc Lymphotoxin beta receptor bound to human IgG1 Fc 
fragment
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Figure 1. Cross-interaction binding assays of soluble TNFRSF and TNFSF recombinant proteins 
of the LIGHT/HVEM/LTβR/DcR3 system
(A) The complete gene encoding mouse HVEM molecule fused to GFP, mouse LTβR-GPI 
or human DcR3-GPI were transfected into HEK-293T cells (red solid lines) and stained with 
FF-mouse LIGHT (upper panel) or Flag-tagged human LIGHT (lower panel). HEK-293T 
cells transfected with the empty plasmid were used as controls (black dotted lines). 
Receptor/ligand interactions were detected with biotinylated anti-Flag mAb (clone M2) plus 
allophycoerythrin-coupled streptavidin.
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(B) 2 × 105 NIH-3T3 cells transduced with pMIG-mouse LIGHT-IRES-GFP (left panel, red 
solid lines) or HEK-293T cells transfected with human LIGHT bound to GFP (right panel, 
red solid lines) were incubated with mHVEM-Ig, mLTbR-Ig or hDcR3-Ig. As negative 
controls, NIH-3T3 or HEK-293T cells were transduced or transfected with the empty 
expression vector (black dotted lines). The ligand/receptor interactions were detected using 
biotinylated anti-mouse IgG2a or anti-human IgG1 followed by allophycocyanin-coupled 
streptavidin.
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Figure 2. LTβR competes with HVEM for binding to the TNFR binding site of LIGHT
(A) LIGHT-transduced NIH-3T3 (2 × 105) cells were incubated with graded concentrations 
of purified sHVEM.IgG2a (left panel) or LTβR.hIgG1 (right panel). The binding of HVEM 
and LTβR to membrane LIGHT was evaluated by flow cytometry with appropriate anti-
mouse and anti-human secondary antibodies. The mean fluorescence intensity (MFI) 
binding of LIGHT receptors to membrane-bound LIGHT was calculated and plotted against 
graded concentrations of HVEM.mIgG2a (left side panel) and LTβR.hIgG1 (left side panel).
(B) To test whether mouse HVEM-Ig and LTβR-Ig bind to the same or overlapping regions 
on mouse LIGHT, 2 × 105 NIH-3T3 transduced cells expressing mouse LIGHT on the cell 
surface were incubated with sHVEM.mIgG2a at 50 μg/ml (left panel) or LTβR.hIgG1 at 10 
μg/ml (right panel) (red solid lines) or with the controls mIgG2a or hIgG1 (black dotted 
lines). In the presence of the inhibitors, either LTβR.hIgG1 at 10 μg/ml (left side panel) or 
sHVEM.mIgG2a at 50 μg/ml (right side panel) was added to the reaction and detected with 
biotinylated anti-human IgG or anti-mouse IgG2a followed by SA-APC.
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Figure 3. Specificity, cross-reactivity and antagonist activity of anti-LIGHT mAbs
(A, left panels) NIH-3T3 cells (2 × 105) were transduced with either pMIG-mouse LIGHT-
IRES-GFP (red solid lines) or control plasmid pMIG-IRES-GFPs (black dotted lines) and 
were incubated with the indicated anti-LIGHT mAbs followed by Cy5-labeled mouse anti-
rat IgG secondary antibody.
(A, right panels) Cross-reactivity of anti-mouse LIGHT mAbs with human LIGHT was 
tested with HEK-293T cells (2 × 105) cotransfected with either pcDNA3.1 plasmid 
harboring human LIGHT fused to GFP (red solid lines) or empty plasmid pcDNA3.1 - GFP 
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(black dotted lines). Binding was detected with Cy5-labeled mouse anti-rat IgG secondary 
antibody.
(B) Mouse LIGHT-transduced NIH-3T3 cells were incubated for 1 h at 37°C with anti-
LIGHT mAbs (clones 10F12, 3G1, 9B7 and 6H12, red solid lines) or isotype-matched 
control rat IgG2a (black dotted lines). Grey shaded histograms represent LIGHT-transduced 
cells incubated with either mIgG2a or hIgG1 as control for the recombinant proteins. In the 
presence of saturating amounts of anti-LIGHT antibodies, the reaction was incubated with 
HVEM-Ig (upper panel) or LTβR-Ig (lower panel) and the binding of receptor.Ig was 
detected with appropriate biotinylated secondary antibodies followed by phycoerythrin-
coupled streptavidin. The reduction of the mean fluorescence intensity (MFI) shown in each 
plot indicates the antagonist functional activity of anti-LIGHT antibodies.
(C) Graded concentrations of soluble recombinant mouse LIGHT were preincubated with a 
saturated amount of anti-mouse LIGHT monoclonal antibody (clone 10F12) for 1 hour at 37 
°C. The antigen/antibody complex was added to LIGHT-transduced cells for 30 minutes at 
37°C, then the reaction was washed and developed with biotinylated mouse anti-rat IgG2a 
and SA-PE. The MFI inhibition of anti-LIGHT binding to membrane LIGHT in the presence 
of graded concentrations of FF-LIGHT is shown.
Graded concentrations of anti-LIGHT mAb were preincubated for 1 hour at 37 °C with an 
amount of mouse FF-mouse LIGHT recombinant protein sufficient to saturate binding to 
membrane-expressed receptors. Then, the antigen/antibody complex was added to HVEM-
transfected CHO cells (D) or LTβR-GPI transfected HEK293T (E) cells for 30 minutes at 
37°C. The reaction was washed and developed with biotinylated mouse anti-Flag mAb (anti-
Flag, clone BioM2) and SA-PE. The MFI inhibition of soluble FF-mouse LIGHT binding to 
HVEM transfected cells or LTβR transfected cells is plotted.
F) Nineteen mouse TNF family ligands fused to the Fc portion of human IgG1 were 
captured in an ELISA plate and revealed with biotinylated 10F12 anti-mLIGHT mAb (top 
panel) or with an anti-human IgG antibody to reveal the presence of the various ligands 
(bottom panel).
G) Preparation of anti-LIGHT (10F12) Fab fragments. 10 μg of 10F12 mAb digested with or 
without immobilized ficin was analyzed by SDS-PAGE and Coomassie blue staining. HC: 
heavy chain. LC: light chain.
H) The Fab fragment of 10F12 mAb at the indicated concentrations was analyzed by surface 
plasmon resonance onto immobilized FF-mouse LIGHT. Fab solutions were applied for 180 
s, and subsequently washed with buffer. The equilibrium dissociation constant KD was 
5.8×10−9 M.
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Figure 4. Mouse LIGHT is expressed upon activation more prominently on CD8 T cells than on 
CD4 T cells and it is also expressed on activated NK cells
C57BL/6 WT or LIGHT-deficient splenocytes were plated at 2 × 105 cells per well in 96-
well plates and were left untreated or stimulated with PMA (50 ng/ml) and ionomycin (500 
ng/ml) for 5 h. Hylite 647-labeled anti-LIGHT mAb (clone 10F12) or Hylite 647-labeled 
isotype control (rat IgG2a) were added to the cells during the incubation. The expression of 
mouse LIGHT was analyzed on living lineage-negative cells for CD19, CD11b and CD11c 
resting and activated CD4+ (upper panel) and CD8+ (lower panel) T cells (A) and on resting 
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and activated NK cells (NKT cells and non-T NK cells) of WT and LIGHT KO after gating 
out CD19+ and CD11c+ cells (B).
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Figure 5. Decreased host anti-donor short-term cytotoxic response in vivo after antibody-
mediated blockade of LIGHT
Isotype control (white bars) and anti-LIGHT-treated (shaded striped bars) WT B6 mice and 
isotype control-treated B6 LIGHT-deficient mice (black bars) received 30 × 106 splenocytes 
of each B6, BALB/c and F1 differentially labeled with CFSE. The percentage of specific 
lysis of the BALB/c and F1 populations relative to the B6 population in spleen (A) and 
peripheral lymph nodes (pLNs) (inguinal plus axillar) (B) was monitored 72 h after cell 
transfer. Data are representative of two independent experiments with three to four mice per 
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group. Bars indicate mean ± SEM and t test was used to compare differences between 
groups.
70×106 splenocytes from B6 WT or LIGHT-deficient mice labeled with 5 μM CFSE were 
injected into F1 recipients, which were treated with isotype control or anti-LIGHT 10F12 
mAb. Three days later, the ratio of absolute number of donor CFSE labeled non-divided/
divided CD4 and CD8 T cells (C) as well as the absolute number of donor CD4 and CD8 T 
cells expressing CD25 was calculated (D). Statistical significance is indicated as follows: *, 
p< 0.05; **, p< 0.005; ***, p< 0.0005 and ns, non-significant.
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